patent expiration

$LLY surged 1,100% in ten years via GLP-1 drugs, but 39x P/E ratio and patent risks loom.

Johnson & Johnson exceeded Q1 2026 expectations and raised guidance, though stock declined as Stelara patent losses offset strong drug sales.

J&J reported 9.9% Q1 revenue growth with raised guidance, though EPS fell 2.5% due to patent losses. Technical setup suggests 20% upside potential supported by strong pipeline expectations.

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

FMC stock tumbled two-thirds amid patent expirations and industry headwinds, but potential acquisition and new products could spark recovery.

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.

Bristol Myers Squibb's 4% dividend yield, well above sector averages and trading 25% below 2022 highs, could compound into seven-figure retirement wealth through consistent reinvestment.

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.